Theriva Biologics Inc. (TOVX)
AMEX: TOVX
· Real-Time Price · USD
0.49
-0.04 (-7.55%)
At close: Jun 12, 2025, 3:59 PM
-7.55% (1D)
| Bid | 0.48 |
| Market Cap | 4.05M |
| Revenue (ttm) | 154K |
| Net Income (ttm) | -24.81M |
| EPS (ttm) | -13.05 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.08 |
| Analyst | Buy |
| Ask | 0.51 |
| Volume | 290,242 |
| Avg. Volume (20D) | 1,371,265 |
| Open | 0.52 |
| Previous Close | 0.53 |
| Day's Range | 0.46 - 0.51 |
| 52-Week Range | 0.40 - 7.25 |
| Beta | 0.83 |
About TOVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TOVX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TOVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-20.59%
Theriva Biologics shares are trading lower after M...
Unlock content with
Pro Subscription
1 month ago
-40.44%
TOVX stock has given up its prior gain. Theriva Biologics shares were trading higher after the company announced VCN-01 was well tolerated with transient and reversible adverse events, meeting the primary safety endpoint.
2 years ago · proactiveinvestors.com
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatmentTheriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food an...
